PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN

Recruitment & Eligibility

Status: Completed

Sex: All

Target Recruitment: 100

Inclusion Criteria

Inclusion Criteria: - Has provided written informed consent, and has the willingness and ability to comply with all study procedures - >= 18 years old - Patients with neutropenic fever who have existing malignancy or have undergone hematopoietic stem cell transplantation - Neutropenic fever is defined as the presence of neutropenia defined by: - Absolute neutrophil count (ANC) < 500 cells/mm3 or has an ANC that is expected to decrease to < 500 cells/mm^3 within 48 hours of trial entry and fever defined as: - Single oral temperature measurement of > 100.4 degree F (38.0 degree C). - Requires hospitalization for IV empiric antibiotic therapy - If female: - Not breastfeeding - Agrees to not attempt to become pregnant during the study. Is surgically sterile or at least 2-years postmenopausal, or if of childbearing potential, has negative screening serum or urine pregnancy test within 5 days - If of childbearing potential (including being < 2 years postmenopausal), is willing to practice sexual abstinence or use an effective dual form of contraception with her partner (eg, 2 barrier methods, barrier method plus hormonal method) during treatment and up 28 days post treatment Exclusion Criteria: - History of any hypersensitivity or allergic reaction to any carbapenem - Fever suspected to be caused by a noninfectious cause (eg, fever related to drug or blood product administration) - Confirmed fungal infection (eg, Pneumocystis jirovecii etiology in patients with pneumonia) that justifies adding additional empiric antimicrobial therapy (eg, antifungals) - Confirmed viral infection that justifies adding additional empiric antiviral therapy (eg, ganciclovir, foscarnet) - Evidence of significant hepatic impairment (any of the following): - Known acute viral hepatitis - Alanine aminotransferase (ALT) level > 5 times the upper limit of normal (x upper limit of normal [ULN]). Total bilirubin > 3 x ULN unless isolated hyperbilirubinemia is directly related to the acute infection or due to known Gilbert disease - Manifestations of end-stage liver disease, such as ascites or hepatic encephalopathy - Known to be human immunodeficiency virus positive - Severely impaired renal function, defined as creatinine clearance (CrCl) =< 30 mL/min estimated by the Cockcroft-Gault formula - Expected requirement for hemodialysis while on study therapy - Received > 36 hours of IV antibacterial therapy (with study drugs) within 72 hours of the initiation of inpatient IV study drug for treatment of suspected infection. Antibiotic prophylaxis and oral antibiotics is allowed. Prophylactic use of antiviral or antifungal medication is permitted - Past or current history of epilepsy or seizure disorder; exception: well-documented febrile seizure of childhood - Evidence of immediately life-threatening disease, progressively fatal disease, or life expectancy of 3 months or less (eg, moribund or with shock unresponsive to fluid replacement) - Unable or unwilling to adhere to the study-specified procedures and restrictions - Any condition that would make the patient, in the opinion of the Investigator, unsuitable for the study (eg, would place a patient at risk or compromise the quality of the data - Participation in any other ongoing imipenem-relebactam trial

Exclusion Criteria

Not provided

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Clinical Outcome in the MITT Analysis Set at EOIV.

Secondary Outcome Measures

Name	Time	Method

Related Trials

The Hunter Humira and Endothelial Function in Early Rheumatoid Arthritis Trial

CompletedPhase 2

A/Prof Stephen Oakley

Updated 1/13/2020

An Investigator-Initiated, Phase II, Multicenter, Open-Label, Single-Arm, Prospective Clinical Trial to Evaluate the Efficacy and Safety of Alternating Bortezomib-Based Regimens in Combination with DaratUMumab followed by Maintenance with Daratumumab in the Frontline Setting of Primary Plasma CEll LEukemIA: A Trial of the Greek Myeloma Study Group

Phase 1

Hellenic Society of Haematology (HSH)

Updated 8/24/2021

An investigator-initiated, multicenter, phase II study to determine the efficacy and safety of brentuximab vedotin in patients with relapsed or refractory CD30-positive cutaneous T-Cell lymphoma

Not Applicable

Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences

Updated 10/17/2023

A PHASE II, SINGLE-CENTRE, INVESTIGATOR-BLIND, PARALLEL GROUP CLINICAL TRIAL TO INVESTIGATE THE EFFICACY AND SAFETY OF 1% CICLOPIROX OLAMINE (BATRAFEN® CREAM), COMPARED TO 1% HYDROCORTISONE ACETATE (HC45® CREAM), COMPARED TO A TOPICAL EMOLLIENT (E45® CREAM), IN THE TREATMENT OF PATIENTS WITH MILD TO MODERATE ATOPIC ECZEMA

Phase 1

Stiefel Laboratories Maidenhead Ltd (commonly known as Stiefel International R&D)

Updated 10/2/2017

A PHASE II, SINGLE-CENTRE, PROSPECTIVE EXPLORATORY TRIAL TO ASSESS THE EFFICACY OF LANREOTIDE AUTOGEL 120 MG IN THE SYMPTOMATIC TREATMENT OF ACUTE RADIATION INDUCED DIARRHEA

Phase 1

niversity Hospital Ghent

Updated 8/20/2018

A pilot study of enalapril in venous malformations

Phase 1

Oslo University Hospital HF

Updated 7/22/2024

Phase II multicenter investigator initiated trial of Convection-enhanced delivery of Nimustine Hydrochloride against brainstem gliomas

Phase 2

Tominaga Teiji

Updated 10/17/2023

A phase II, open, single centre, exploratory study to evaluate the safety and immunogenicity of one booster dose of a GSK Biologicals’ Hepatitis B vaccine Engerix™-B or a of GSK Biologicals’ HIV candidate vaccine (732461), administered intramuscularly, in conjunction with the administration of a single oral dose of chloroquine in healthy adults. - EARLY-CLINRES-004

GlaxoSmithKline Biologicals

Updated 10/7/2014

A single centre, exploratory, phase II, cross-over, randomised trial, evaluating the effect of spontaneously breathing Helium/Oxygen (65%/35%), to either spontaneously breating Nitrogen/Oxygen (65%/35%) on the Six-Minute Walking Distance in severe COPD patients - Lung Function Exercising

Air Liquide

Updated 9/23/2013

A multicenter, investigator-initiated phase II clinical trial involving administration of a cross-linked gelatin hydrogel containing recombinant human basic fibroblast growth factor (rh-bFGF) to prevent the collapse of the femoral head

Phase 2

Haruhiko Akiyama, Gifu University Hospital

Updated 10/17/2023

PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN

Recruitment & Eligibility

Study & Design

Related Trials

The Hunter Humira and Endothelial Function in Early Rheumatoid Arthritis Trial

An investigator-initiated, multicenter, phase II study to determine the efficacy and safety of brentuximab vedotin in patients with relapsed or refractory CD30-positive cutaneous T-Cell lymphoma

A PHASE II, SINGLE-CENTRE, PROSPECTIVE EXPLORATORY TRIAL TO ASSESS THE EFFICACY OF LANREOTIDE AUTOGEL 120 MG IN THE SYMPTOMATIC TREATMENT OF ACUTE RADIATION INDUCED DIARRHEA

A pilot study of enalapril in venous malformations

Phase II multicenter investigator initiated trial of Convection-enhanced delivery of Nimustine Hydrochloride against brainstem gliomas

A single centre, exploratory, phase II, cross-over, randomised trial, evaluating the effect of spontaneously breathing Helium/Oxygen (65%/35%), to either spontaneously breating Nitrogen/Oxygen (65%/35%) on the Six-Minute Walking Distance in severe COPD patients - Lung Function Exercising

A multicenter, investigator-initiated phase II clinical trial involving administration of a cross-linked gelatin hydrogel containing recombinant human basic fibroblast growth factor (rh-bFGF) to prevent the collapse of the femoral head

Clinical Trial Alerts

Clinical Trial Alerts